Accelerating response to antidepressant treatment in depression: A review and clinical suggestions

被引:55
作者
Nakajima, Shinichiro
Suzuki, Takefumi [2 ,3 ]
Watanabe, Koichiro
Kashima, Haruo
Uchida, Hiroyuki [1 ,2 ]
机构
[1] Keio Univ, Sch Med, Dept Neuropsychiat, Shinjuku Ku, Tokyo 1608582, Japan
[2] Ctr Addict & Mental Hlth, Geriatr Mental Hlth Program, Toronto, ON, Canada
[3] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
关键词
Antidepressant; Early non-response; Major depressive disorder; Predictor; Switching; SEROTONIN REUPTAKE INHIBITOR; TREATING MAJOR DEPRESSION; EARLY IMPROVEMENT; PROMOTER POLYMORPHISM; DOUBLE-BLIND; METAANALYSIS; FLUOXETINE; DISORDER; EFFICACY; AUGMENTATION;
D O I
10.1016/j.pnpbp.2009.12.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: The primary objective of this article is to review the literature regarding the speed of response to antidepressant drugs and potential strategies to accelerate the antidepressant response in new antidepressant-free patients with depression. Based on these data, we try to propose both an effective and safe antidepressant treatment strategy to alleviate depressive symptoms at the earliest opportunity. Data sources: Data were identified by searches of Medline (1966 to September 2009) and references from relevant articles and books. Search terms included depression, antidepressant, predictor, response, onset, acceleration, and augmentation. As our focus was on the acute phase treatment of depression, articles relevant to treatment-resistant depression were excluded. Only articles written in English or Japanese were consulted. Data selection: Studies, reviews, and books pertaining to the treatment of depression with a special regard to accelerating therapeutic effects were selected. Data synthesis: Most of the available treatment guidelines for major depressive disorders recommend the continuous use of antidepressants for 4 to 8 weeks based on the idea of a delayed onset of response to these drugs. Contrary to this conventional belief, the recent data indicate that antidepressants start to exert their effects within 2 weeks and early non-response could predict a subsequent unfavorable outcome. Conclusions: These findings suggest the need of revisiting the timing of an antidepressant switch for early non-responders, whereby switching could be commenced in as early as 2 weeks. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:259 / 264
页数:6
相关论文
共 66 条
[1]   Sertraline versus paroxetine in major depression:: Clinical outcome after six months of continuous therapy [J].
Åberg-Wistedt, A ;
Ågren, H ;
Ekselius, L ;
Bengtson, F ;
Åkerblad, AC .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (06) :645-652
[2]   Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature [J].
Altshuler, LL ;
Bauer, M ;
Frye, MA ;
Gitlin, MJ ;
Mintz, J ;
Szuba, MP ;
Leight, KL ;
Whybrow, PC .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (10) :1617-1622
[3]   Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines [J].
Anderson, IM ;
Nutt, DJ ;
Deakin, JFW .
JOURNAL OF PSYCHOPHARMACOLOGY, 2000, 14 (01) :3-20
[4]  
[Anonymous], 2000, Am J Psychiatry, V157, P1
[5]   Evidence that the SSRI dose response in treating major depression should be reassessed: A meta-analysis [J].
Baker, CB ;
Tweedie, R ;
Duval, S ;
Woods, SW .
DEPRESSION AND ANXIETY, 2003, 17 (01) :1-9
[6]   Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials [J].
Ballesteros, J ;
Callado, LF .
JOURNAL OF AFFECTIVE DISORDERS, 2004, 79 (1-3) :137-147
[7]  
Bauer Michael, 2002, World J Biol Psychiatry, V3, P5, DOI 10.3109/15622970209150599
[8]   Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis [J].
Beasley, CM ;
Koke, SC ;
Nilsson, ME ;
Gonzales, JS .
CLINICAL THERAPEUTICS, 2000, 22 (11) :1319-+
[9]  
BOWDEN CL, 1993, J CLIN PSYCHOPHARM, V13, P305
[10]   Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors [J].
Cooper-Kazaz, Rena ;
Lerer, Bernard .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 (05) :685-699